Company news
Biodesix, Inc. news in 2023
Biodesix, Inc.'s news releases, calls and decks from 2023, newest first.
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method
November 13, 2023
Biodesix Announces Third Quarter 2023 Results and Highlights
November 6, 2023
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
October 23, 2023
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
September 6, 2023
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
August 21, 2023
Biodesix Announces Second Quarter 2023 Results and Highlights
August 6, 2023
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
July 23, 2023
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
July 11, 2023
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
July 5, 2023
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
June 26, 2023
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
May 31, 2023
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
May 24, 2023
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
May 17, 2023
Biodesix Announces First Quarter 2023 Results and Highlights
May 10, 2023
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
April 26, 2023
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
March 5, 2023
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 20, 2023